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Abstract
5α-Reductases irreversibly catalyse A-ring reduction of pregnene steroids, including 
glucocorticoids and androgens. Genetic disruption of 5α-reductase 1 in male mice 
impairs glucocorticoid clearance and predisposes to glucose intolerance and hepatic 
steatosis upon metabolic challenge. However, it is unclear whether this is driven 
by changes in androgen and/or glucocorticoid action. Female mice with transgenic 
disruption of 5α-reductase 1 (5αR1-KO) were studied, representing a ‘low androgen’ 
state. Glucocorticoid clearance and stress responses were studied in mice aged 6 
months. Metabolism was assessed in mice on normal chow (aged 6 and 12 m) and also 
in a separate cohort following 1-month high-fat diet (aged 3 m). Female 5αR1-KO 
mice had adrenal suppression (44% lower AUC corticosterone after stress), and 
upon corticosterone infusion, accumulated hepatic glucocorticoids (~27% increased 
corticosterone). Female 5αR1-KO mice aged 6 m fed normal chow demonstrated insulin 
resistance (~35% increased area under curve (AUC) for insulin upon glucose tolerance 
testing) and hepatic steatosis (~33% increased hepatic triglycerides) compared with 
controls. This progressed to obesity (~12% increased body weight) and sustained 
insulin resistance (~38% increased AUC insulin) by age 12 m. Hepatic transcript profiles 
supported impaired lipid β-oxidation and increased triglyceride storage. Female 
5αR1-KO mice were also predisposed to develop high-fat diet-induced insulin resistance. 
Exaggerated predisposition to metabolic disorders in female mice, compared with 
that seen in male mice, after disruption of 5αR1 suggests phenotypic changes may be 
underpinned by altered metabolism of glucocorticoids rather than androgens.
Introduction
5α-Reductases catalyse the irreversible A-ring reduction 
of pregnene steroids and hence regulate the levels of 
active steroids and their metabolites within tissues 
(Russell & Wilson 1994). There are three isozymes 
of 5αRs, with types 1 and 2 being best characterised 
(Godoy et  al. 2011). The 5α-dihydro metabolite 
(DHT) is a more potent androgen than testosterone. 
The 3α,5α-metabolites of glucocorticoids retain some 
anti-inflammatory properties of the original steroid 
(corticosterone in rodents and cortisol in humans), 
but lack many metabolic properties (McInnes et  al. 
2004, Yang et  al. 2011). Given the potent effects of 
both glucocorticoids and androgens on metabolic 
homeostasis, there has been recent interest in the 
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consequences of inhibition of 5αRs on metabolic health. 
This has implications for men receiving 5αR inhibitors 
for chronic treatment of prostatic disease or women 
receiving these drugs for hirsutism. Furthermore, 
5α-reduction of steroid hormones is increased in obesity 
(Andrew et al. 1998, Fraser et al. 1999) and polycystic 
ovarian syndrome (PCOS) (Stewart et al. 1990).
5αR1 is the dominant isozyme in rodent metabolic 
tissues, and male mice with global genetic disruption of 
this enzyme (but not of 5αR2) develop obesity and insulin 
resistance, with increased susceptibility to liver steatosis, 
fibrosis and hepatocellular carcinoma (Dowman et  al. 
2013, Livingstone et  al. 2015). These findings translate 
into humans, where dutasteride (a dual 5αR inhibitor) 
induces peripheral insulin resistance and hepatic lipid 
accumulation (Upreti et al. 2014, Hazlehurst et al. 2016). 
Questions remain as to whether these adverse effects 
result from changes in glucocorticoid and/or androgen 
signalling or indeed both. Insulin resistance is a feature 
of both excess glucocorticoid production, for example in 
Cushing’s Syndrome, and also low circulating testosterone 
with ageing (Cheung et al. 2015).
In vivo dissection of the distinct contributions 
of androgens and glucocorticoids to the metabolic 
phenotype in the 5αR1-KO mice is difficult. There is 
considerable overlap in the responses to glucocorticoid 
and androgens amongst transcripts of hepatic genes 
regulating carbohydrate and lipid homeostasis (Dowman 
et  al. 2013). In Zucker rats, castration limits insulin 
resistance induced by 5αR inhibition by finasteride (a 
non-selective 5α-reductase inhibitor in rodents (Thigpen 
& Russell 1992)) but does not attenuate the induction of 
hepatic steatosis, implying that changes in glucocorticoid 
signalling may underpin non-alcoholic fatty liver disease 
in 5αR1 deficiency (Livingstone et  al. 2015). Here, we 
investigate whether 5αR1 deficiency in female mice, 
representative of ‘a low androgen’ state, causes similar 
metabolic disturbances to males.
Materials and methods
Chemicals were from Sigma unless stated, steroids from 
Steraloids (Newport, RI, USA) and HPLC-grade solvents 
from Thermo Fisher Scientific.
Animal husbandry
Embryos (C57Bl6/SvEv/129) with targeted disruption 
of 5αR1 (Jackson Laboratory) (Mahendroo et  al. 1996) 
were re-derived (Livingstone et  al. 2014) and allowed 
free access to double-filtered drinking water and 
standard chow (7.4% fat, 4% sucrose; RM1, Special Diet 
Services, Witham, Essex, UK), unless otherwise stated. 
At the end of experiments animals were decapitated 
(08:00–11:00 h), trunk blood was collected and tissues 
were wet weighed and either snap-frozen or fixed in 
formalin (adrenal, thymus). All experiments were 
conducted under authority of UK Home Office licence 
and were subject to internal ethical review by named 
veterinary surgeons at the University of Edinburgh.
HPA function in 5αR1-deficient mice
Basal nadir (08:00 h) and zenith (19:00 h) corticosterone 
was assessed in blood (mice aged 12  m, n = 12/group), 
collected by tail nick. A separate cohort of mice 
(n = 12/group) underwent acute restraint stress (15 min), 
and serial blood samples were taken up to 90 min after the 
onset of stress (Livingstone et al. 2014). Mice were culled 
one week after testing.
Glucocorticoid clearance in 5αR1-deficient mice
Female 5αR1-KO mice and wild-type (WT) controls 
(age 3–4  m, n = 7–8/group) underwent bilateral 
adrenalectomy to remove endogenous glucocorticoids 
and had a fixed rate corticosterone infusion by Alzet 
osmotic mini-pump (100 µg corticosterone/day in 1:1 
DMSO:propylene glycol; Charles River) to assess steady 
state corticosterone clearance rate (Livingstone et al. 2014).
Metabolic function in 5αR1-deficient mice
Female WT and 5αR1-KO mice were fed standard chow 
from weaning, and at age 6 months (n = 19–20/group), 
free ambulatory behaviour was assessed in home cages 
containing single mice, in a recording frame (Linton 
Instruments, Diss, Norfolk, UK) overnight (14.5 h) 
and quantified using AMON software. Animals were 
re-housed in groups, after testing. One week later, 
mice underwent glucose tolerance testing (GTT: 2 g 
glucose/kg body weight i.p., after a 6-h fast) and were 
culled two days later. Further mice (littermates of male 
mice previously reported (Livingstone et al. 2015)) were 
aged to 12  m, subjected to GTT as above and culled 
(n = 15/group).
A further cohort of mice aged 3 m were fed high-fat 
sucrose (58% kcal fat and 13% kcal sucrose) or control 
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diet (10.5% kcal fat, 0% kcal sucrose; Research Diets Inc, 
New Brunswick, NJ, USA) for 4 weeks, subjected to GTT as 
above and culled (n = 10–18/group).
Laboratory analyses
In clearance studies, corticosterone in plasma, liver and 
brain was quantified by liquid chromatography tandem 
mass spectrometry (Livingstone et  al. 2014). Otherwise, 
corticosterone was measured by ELISA (Enzo Life Sciences, 
Exeter, Devon, UK), testosterone by radioimmunoassay 
(Corker & Davidson 1978), insulin by ELISA (Crystal 
Chem Inc, Downers Grove, IL, USA), triglycerides and 
glucose (Thermo Fisher Scientific) and NEFAs (Zen-Bio, 
Research Triangle Park, NC, USA) spectrophotometrically 
(Livingstone et  al. 2015). Hepatic glucocorticoid-
metabolising enzyme activity was measured as described 
previously (Livingstone et al. 2014). Transcript abundance 
was measured by quantitative PCR using the standard 
curve method, except for Crh (corticotrophin-releasing 
hormone), which was measured by in situ hybridisation 
(Livingstone et  al. 2014). PCR assay details and gene 
abbreviations are given in Supplementary Table  1 (see 
section on supplementary data given at the end of this 
article). qPCR results were normalised for the abundance 
of reference genes (liver; mean of 18S ribosomal RNA and 
Actb: hypothalamus; Gapdh and pituitary; Tbp), which 
were not different between groups.
Statistical analysis
Data are represented as mean ± s.e.m. Groups were 
compared by Student’s t tests or ANOVA (with Fisher’s 
post hoc where appropriate), as indicated in the text.
Results
Glucocorticoid clearance in female 5αR1-KO mice
Deficiency of 5αR1 in the liver was confirmed by 
qPCR (Table  1), with mRNA for 5αR1 below the limit 
of quantitation in 5αR1-KO mice meaning transcript 
abundance was at least 100-fold less than that in 
wild-type mice. Other enzymes involved with hepatic 
clearance of glucocorticoids (11β-hydroxysteroid-
dehydrogenase 1,5β-reductase) were not altered by 
genotype (Table 1).
In adrenalectomised mice undergoing fixed infusion 
with corticosterone, circulating corticosterone levels 
were not significantly higher in 5αR1-KO than WT 
mice (166 ± 20 vs 157 ± 47 nM); however, corticosterone 
levels were elevated in 5αR1-KO mice in the liver 
Table 1 Morphometry in female 5αR1-KO and wild-type mice, aged 6 and 12 months.
6 months 12 months
WT 5αR1-KO WT 5αR1-KO
Endocrine parameters
 Adrenal gland (mg) 2.3 ± 0.3 2.3 ± 0.3
 Thymus (mg) 34.1 ± 2.3 34.9 ± 2.9
 Plasma testosterone (pg/mL) 66 ± 10 123 ± 24*
Liver glucocorticoid metabolism
 11βHSD1 velocity (nmol/mg/h) 20.1 ± 2.3 16.5 ± 1.1
 5β-Reductase velocity (pmol/mg/h) 238 ± 17 254 ± 12
 Hsd11b1 (11βHSD1) transcript# 0.81 ± 0.08 0.85 ± 0.10
 Akr1d1 (5β-reductase) transcript# 0.77 ± 0.14 0.98 ± 0.09
 Srd5a1 (5α-reductase 1) transcript# 2.13 ± 0.21 <0.024*** (LOQ)
Metabolic parameters
 Body weight (g) 26.7 ± 0.53 28.4 ± 0.58* 32.4 ± 0.85 37.6 ± 1.91*
 Food intake (g/day) 3.45 ± 0.19 3.10 ± 0.26 4.25 ± 0.10 4.12 ± 0.09
 Liver (mg) 995 ± 64 1083 ± 59 1340 ± 49 1593 ± 49*
 Omental adipose (mg) 30 ± 3 41 ± 19 55 ± 10 51 ± 10
 Mesenteric adipose (mg) 391 ± 25 448 ± 26 499 ± 45 610 ± 90
 Gonadal adipose (mg) 807 ± 65 1016 ± 57* 1066 ± 104 1953 ± 387*
 Subcutaneous adipose (mg) 562 ± 53 718 ± 67 455 ± 39 684 ± 82*
 Total adipose (g) 1.80 ± 0.12 2.21 ± .012* 2.08 ± 0.18 3.65 ± 0.64*
 Hepatic triglycerides (µmol/g) 15.2 ± 1.5 20.2 ± 2.2* 23.9 ± 1.7 30.7 ± 2.6*
Data are mean ± s.e.m., compared by Student’s t-test. *P  < 0.05, ***P < 0.001 for effect of genotype. N = 10–15/group. LOQ = limit of quantitation. 
TAG = triglycerides. # denotes relative abundance of mRNA normalised to the mean of reference genes (18S ribosomal RNA and Actb), which did not 
differ between groups.
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(0.29 ± 0.028 vs 0.21 ± 0.013 nmol/g; P = 0.02) and in the 
brain (0.36 ± 0.052 vs 0.21 ± 0.023 pmol/g; P = 0.02).
HPA axis response in female 5αR1-KO mice
Basal circulating corticosterone concentrations were not 
different between genotypes at either nadir (08:00 h) or 
zenith (19:00 h, Fig. 1A). After acute restraint, the AUC for 
the stress response was reduced in 5αR1-KO compared with 
WT mice (Fig. 1B, C). In the hypothalami from KO mice 
(Fig. 1D), there was reduced abundance of transcript for 
Avp and Crh, and a trend for a decrease in glucocorticoid 
receptor (GR: Nr3c1). Crhr1 transcript abundance in the 
pituitary was reduced in KO mice (Fig. 1E), but there was 
no difference in either GR or mineralocorticoid receptor 
(MR: Nr3c2).
Figure 2
Metabolic dysfunction in female mice deficient in 5α-reductase 1. Female mice deficient in 5α-reductase 1 (KO) aged 6 m had normal fasting glucose and 
maintained their circulating glucose concentrations during glucose tolerance test (A); however, their insulin levels were higher during the test than 
wild-type mice (WT) (B). The area under the curve (AUC) for glucose was not altered between genotypes (C) but was increased for insulin in 5αR1-KO 
(D). At age 12 m, KO mice still had normal fasting glucose and response during GTT (E), with AUC unaffected by genotype (G). However, the area under 
the curve (AUC) for insulin was increased during the GTT in KO mice (F, H). Hepatic transcript profiling by quantitative PCR (I). Data are presented with 
WT data normalised to 1 for clarity, but statistical comparisons were made on raw data. N = 15–20/group. Data are mean ± s.e.m., compared by ANOVA in 
A, B, E and F, with post hoc comparisons in B and F, and by Student’s t-test in C, D, G, H and I. *P < 0.05, **P < 0.01 vs WT. WT = filled bars/symbols and 
solid lines, KO = open bars/symbols and dashed lines.
Figure 1
Dysregulation of the HPA axis in female mice deficient in 5α-reductase 1. (A) Female mice deficient in 5α-reductase 1 (KO) had normal plasma 
corticosterone at 08:00 h (nadir) and 19:00 h (zenith). (B) The increase in corticosterone in response to acute stress (duration of stress 15 min, indicated  
by dark bar) was attenuated in female mice deficient in 5αR1 (KO) compared with wild-type controls (WT), with a smaller area under the curve (C).  
(D) Abundance of mRNA transcript for Avp (arginine vasopressin) and Crh (corticotrophin-releasing hormone) were reduced in hypothalamus from KO 
mice, and there was a trend (P = 0.06) for reduced expression of glucocorticoid receptor (GR: Nr3c1). (E) Transcript for Crhr1 (CRH-receptor 1) was  
lower in pituitaries from KO mice, but there was no difference in expression of GR or mineralocorticoid receptor (MR: Nr3c2). Data are mean ± s.e.m., 
N = 8–15 and compared by Student’s t-test (A, C, D and E), or ANOVA with post hoc comparisons (B). *P < 0.05 and **P < 0.01 vs WT. WT = filled  
bars/symbols and solid lines, KO = open bars/symbols and dashed lines.
33Research d e w livingstone and others 5α-Reductase 1 and  
metabolic risk
DOI: 10.1530/JOE-16-0125
Jo
u
rn
al
o
f
En
d
o
cr
in
o
lo
g
y
http://joe.endocrinology-journals.org © 2017 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
232:1
Metabolic homeostasis in female 5αR1-KO mice
At 6 months of age, female 5αR1-KO mice were heavier 
than WT controls (Table  1) and had increased adipose 
tissue. Hepatic triglyceride content was higher in 5αR1-KO 
mice, but liver weight was not significantly increased. 
Total nocturnal ambulatory activity did not differ between 
genotypes (WT vs 5αR1-KO; total active time 7583 ± 531 
vs 7362 ± 580 s; distance travelled 360 ± 41 vs 321 ± 60 m), 
and neither did food intake (Table 1).
Fasting glucose was not different between genotypes 
(Fig.  2A), but there was a trend (P = 0.06) for higher 
fasting insulin in 5α-R1-KO mice (Fig. 2B). During the 
GTT, glucose levels were normal in 5α-R1-KO mice 
(Fig. 2A, C), but at the expense of higher plasma insulin 
(Fig. 2B, D).
As animals aged to 1  year, female 5αR1-KO mice 
remained heavier, gaining excess adipose throughout, but 
without consuming extra calories (Table 1). Liver weights 
and hepatic triglyceride content were higher in 5αR1-KO 
than WT mice (Table 1). On GTT, glucose was not different 
between genotypes (Fig.  2E, G), but again, insulin was 
elevated (Fig. 2F, H). NEFA suppression during GTT was 
not different between WT and 5αR1-KO mice (Δ15–0 min: 
0.44 ± 0.08 vs 0.28 ± 0.06 µM). Hepatic transcripts of 
Acc1, Agpat2, Cpt 2 and Dgat2 (Fig. 2H) were increased in 
abundance in 5αR1-KO mice vs WT, with a trend towards 
increased Ppar α.
Young (age 3 m) 5αR1-KO mice fed control diet were 
not heavier than WT (22.69 ± 0.63 vs 23.38 ± 0.61 g; 
P = 0.6), but when both genotypes were fed high-fat diet, 
5αR1-KO were significantly heavier than WT (25.71 ± 0.61 
vs 23.71 ± 0.57g; P<0.05). On GTT, glucose concentrations 
were not affected by genotype or diet (Fig. 3A, B). Insulin 
concentrations were not different in control diet-fed 
mice, but were significantly higher in the 5αR1-KO mice 
receiving high-fat diet vs WT (Fig. 3C, D).
Discussion
Female 5αR1-KO mice are more susceptible to 
metabolic dysfunction than wild-type mice, both 
with ageing when fed normal chow and when fed 
high-fat high-sucrose diet. Female 5αR1-KO mice 
thus appear even more metabolically vulnerable than 
male 5αR1-KO mice; in two separate studies, male 
5αR1-KO mice fed control diets for 6 months did not 
exhibit a metabolic phenotype (Dowman et  al. 2013, 
Livingstone et al. 2015). Similar to male mice deficient 
in 5αR1 (Livingstone et al. 2014), female 5αR1-KO mice 
accumulated active glucocorticoid hormones within 
their livers and brains, indicating an impairment in 
clearance of corticosterone. Reduced glucocorticoid 
response to acute stress indicates that this alteration in 
clearance may be sufficient to incur adrenal suppression, 
as seen in male 5αR1-KO mice (Livingstone et al. 2014), 
and hypothalamic and pituitary transcript profiles are 
consistent with a decrease in HPA axis drive.
Disruption of 5αR1 in male mice adversely affects 
metabolism, but metabolic disturbance was only 
revealed after prolonged high-fat feeding (6  months), 
when they developed steatosis and insulin resistance, 
with exaggerated susceptibility to more severe liver 
disease (Dowman et  al. 2013, Livingstone et  al. 2015). 
However, female mice lacking 5αR1 developed similar 
features, with steatosis and glucose intolerance evident 
in chow-fed mice, without the requirement for stimulus 
of a metabolic dietary challenge. Female 5αR1-KO mice 
aged 6 months were overweight, with impaired insulin 
Figure 3
Insulin sensitivity in female mice deficient in 5α-reductase 1 aged 3 m after high-fat diet. Female mice deficient in 5α-reductase 1 (KO) and their 
wild-type controls (WT) aged 3m were fed high-fat (HFD) or control diet (CD). After 1 m of experimental diet, glucose concentrations during glucose 
tolerance test (GTT) (A) and the area under the curve for glucose during the GTT (B) were not affected by genotype or diet. However, the area under  
the curve (AUC) for insulin during the GTT was increased specifically in KO mice fed high-fat diet (C, D). N = 10–18/group, data are mean ± s.e.m., 
compared by two-way ANOVA with post hoc testing. *P < 0.05 on ANOVA, #P < 0.05 compared with all other groups. n.s. is not significant. WT = filled  
bars/symbols and solid lines, KO = open bars/symbols and dashed lines.
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sensitivity and hepatic steatosis and this progressed 
further by 1  y. Similar to male mice, adipose insulin 
sensitivity was maintained, as evidenced by normal 
suppression of NEFAs during GTT, suggesting that 
liver may be the primary site underpinning metabolic 
disturbance in 5αR1-KO mice. In addition, just one 
month of high-fat diet in young female mice (3 m) was 
sufficient to reveal increased susceptibility to weight 
gain and insulin resistance in 5αR1-KO mice, whereas 
having no effect in WT mice.
The hepatic transcript profile of the female mice 
supported the concept of increased hepatic storage of lipid 
with reduced abundance of Dgat2 mRNA. However, Acc1, 
generating malonyl CoA as a suppressor of β-oxidation, 
was also increased in females. Although this bore some 
similarities to the changes in male 5αR1-KO mice, direct 
gender comparisons cannot be made because previous 
males (Livingstone et al. 2015) were subject to different 
experimental conditions.
Female mice were studied to address the question of 
which hormonal change underpinned the phenotype of 
adverse metabolism in males, given both glucocorticoids 
and androgens (and indeed other hormones) are enzyme 
substrates with potent effects to regulate metabolism. 
Liver and brain glucocorticoid levels were increased in 
the female 5αR1-KO mice similar to males, by ~30–50% 
during chronic infusion of corticosterone (Livingstone 
et al. 2014). As with males, impaired hepatic clearance 
of corticosterone in female 5αR1-KO mice appeared of 
sufficient magnitude to reduce drive through the HPA 
axis, as supported by the reported reduced abundance 
of hypothalamic transcript encoding AVP and CRH and 
reduced pituitary expression of CRHR1 in 5αR1-KO mice 
and the subsequent adrenal suppression manifested in 
attenuated adrenal responses to stress compared with 
WT. Differences might have been anticipated to be less 
as female mice, unlike rats (Gustafsson & Stenberg 1974) 
and humans (Andrew et al. 1998, Fraser et al. 1999), have 
reduced expression of hepatic 5α-R1 mRNA compared 
with males. Furthermore, the presence of cyclical 
progesterone may have changed the competition 
between 5αR1 substrates for clearance (Andersson & 
Russell 1990, Normington & Russell 1992) between 
female vs male mice, with corticosterone binding with 
considerably less affinity than progesterone for 5αR1 
(Normington & Russell 1992), but not 5β-reductase 
(Kondo et al. 1994).
The fact that female 5αR1-KO mice developed 
metabolic dysfunction at a younger age than their 
male counterparts, while sustaining similar changes in 
hepatic glucocorticoid levels, (Livingstone et al. 2014) 
points to the changes in androgen metabolism 
secondary to 5αR1 deficiency being protective. Indeed 
had androgens been the principle driver of adverse 
metabolism, the phenotype would be expected to be 
less pronounced in females than in males; however, the 
phenotype was more marked in females, pointing to 
the changes in androgen metabolism secondary to 5αR1 
deficiency being protective. Female 5αR1-KO mice had 
increased testosterone vs WT (Table 1), but overall levels 
were more than ten-fold lower than those in males. 
The subtle increased testosterone was associated with 
increased oestradiol levels, likely through increased 
availability of aromatase substrate (Mahendroo et  al. 
1997). However, increased circulating oestradiol is 
unlikely to explain the adverse metabolic changes 
observed as reduced, rather than excess, aromatase 
activity promotes fatty liver and insulin resistance in 
mouse models, as evident in aromatase-knockout mice 
(Jones et al. 2000).
Ideally, this experiment would have also been 
performed in gonadectomised male mice to minimise 
changes in androgens; however, attempts to do this were 
unsuccessful. Upon gonadectomy, the wild-type mice 
resisted high-fat diet, neither gaining excess weight nor 
having raised insulin. Signalling through the androgen 
receptor (AR) may play a protective role, as disruption 
of AR predisposes to late-onset obesity (Sato et al. 2015), 
but more so in males than females (when a high-fat diet 
is required (Fagman et al. 2015)). Disruption of hepatic 
AR also predisposes male but not female mice to hepatic 
steatosis (Lin et  al. 2008), emphasising the important 
role of androgens in metabolic regulation within 
liver, the major site of 5αR1 expression. Here, female 
5αR1-KO mice may be more susceptible to developing 
steatosis due to higher dependency on small amounts 
of DHT formed through 5αR1 for AR stimulation than 
males, who would be protected by their greater pool 
of testosterone. After inhibition/disruption of 5αR1, 
excess testosterone may also be converted to oestradiol 
by aromatase; mice lacking 5αR1 have increased levels 
of oestrogens (Mahendroo et  al. 1997), as do men 
receiving 5αR1 inhibitors (Upreti et  al. 2014). This is 
of sufficient magnitude to cause parturition defects 
in 5αR1-KO mice (Mahendroo et  al. 1997) and might 
attenuate the adverse changes in metabolism in 
male mice.
In a previous attempt to dissect the contribution of 
androgens to the metabolic phenotype, pharmacological 
inhibitors of 5αRs were administered to castrated Zucker 
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rats (Livingstone et al. 2015). Under these circumstances, 
insulin resistance was less marked after 5αR inhibition, but 
hepatic steatosis was still present. This was interpreted as 
the hepatic lipid phenotype being driven by accumulation 
of excess glucocorticoids, whereas aspects of peripheral 
insulin resistance observed were ameliorated by changes 
in androgen metabolism. The data in female 5αR1-KO 
mice support the adverse changes in metabolism being 
driven by glucocorticoids.
In conclusion, studying female mice as a ‘low 
androgen’ state shows that changes in sex steroid 
metabolism are not the primary drivers of adverse 
changes in metabolism observed after deficiency or 
inhibition of 5αR1 and supports the notion that 5αR1 
plays a critical role in regulating tissue glucocorticoid 
action. Variations in 5αR1 activity in obesity may have 
therefore have important consequences for onset and 
progression of metabolic liver disease, and these may be 
more influential in women or hypogonadal men. Women 
may be particularly susceptible to adverse metabolic 
effects of dual 5α-reductase inhibitors, should they be 
prescribed for hirsutism in the future (Azzouni et  al. 
2013). Close monitoring of insulin sensitivity in these 
patient subgroups when receiving dual 5αR inhibitors 
may be necessary.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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